P/E ratio for Utah Medical Products (UTMD)
P/E ratio as of April 2024 (TTM): 14.2
According to Utah Medical Products's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.2493. At the end of 2022 the company had a P/E ratio of 22.2.
P/E ratio history for Utah Medical Products from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 22.2 | -10.29% |
| 2021 | 24.7 | -11.85% |
| 2020 | 28.0 | 2.55% |
| 2019 | 27.4 | 63.43% |
| 2018 | 16.7 | -53.25% |
| 2017 | 35.8 | 59.03% |
| 2016 | 22.5 | 21.01% |
| 2015 | 18.6 | -6.57% |
| 2014 | 19.9 | 5.3% |
| 2013 | 18.9 | 44.84% |
| 2012 | 13.1 | -1.41% |
| 2011 | 13.2 | -18.29% |
| 2010 | 16.2 | -4.99% |
| 2009 | 17.1 | 45.31% |
| 2008 | 11.7 | -20.61% |
| 2007 | 14.8 | -7.19% |
| 2006 | 15.9 | -4.75% |
| 2005 | 16.7 | 71.97% |
| 2004 | 9.73 | 70.8% |
| 2003 | 5.69 | -56.47% |
| 2002 | 13.1 | 12.46% |
| 2001 | 11.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -26.85% | 🇺🇸 USA |
 Teleflex TFX | 24.2 | 70.13% | 🇺🇸 USA |
 Cooper Companies COO | 16.1 | 13.25% | 🇺🇸 USA |
 Merit Medical MMSI | 43.2 | 202.86% | 🇺🇸 USA |
 CONMED CNMD | 35.4 | 148.29% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.